GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Giant Biogene Holding Co Ltd (HKSE:02367) » Definitions » Net Cash per Share

Giant Biogene Holding Co (HKSE:02367) Net Cash per Share : HK$3.53 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Giant Biogene Holding Co Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Giant Biogene Holding Co's Net Cash per Share for the quarter that ended in Dec. 2023 was HK$3.53.

The historical rank and industry rank for Giant Biogene Holding Co's Net Cash per Share or its related term are showing as below:

HKSE:02367' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 10.08   Med: 12.97   Max: 15.85
Current: 14.16

During the past 5 years, the highest Price-to-Net-Cash Ratio of Giant Biogene Holding Co was 15.85. The lowest was 10.08. And the median was 12.97.

HKSE:02367's Price-to-Net-Cash is ranked worse than
64.33% of 314 companies
in the Consumer Packaged Goods industry
Industry Median: 9.905 vs HKSE:02367: 14.16

Giant Biogene Holding Co Net Cash per Share Historical Data

The historical data trend for Giant Biogene Holding Co's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Giant Biogene Holding Co Net Cash per Share Chart

Giant Biogene Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
0.19 -0.28 0.49 2.12 3.53

Giant Biogene Holding Co Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Net Cash per Share Get a 7-Day Free Trial 0.49 - 2.12 2.65 3.53

Competitive Comparison of Giant Biogene Holding Co's Net Cash per Share

For the Household & Personal Products subindustry, Giant Biogene Holding Co's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Giant Biogene Holding Co's Price-to-Net-Cash Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Giant Biogene Holding Co's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Giant Biogene Holding Co's Price-to-Net-Cash falls into.



Giant Biogene Holding Co Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Giant Biogene Holding Co's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(4133.144-658.486-9.746)/981.638
=3.53

Giant Biogene Holding Co's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(4133.144-658.486-9.746)/981.638
=3.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Giant Biogene Holding Co  (HKSE:02367) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Giant Biogene Holding Co Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Giant Biogene Holding Co's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Giant Biogene Holding Co (HKSE:02367) Business Description

Traded in Other Exchanges
N/A
Address
No. 1855, Shanglin Yuan 7th Road, Chang’an District, Shaanxi Province, Xi’an, CHN
Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.
Executives
Refulgence Holding Limited 2201 Interest of corporation controlled by you
Juzi Holding Co., Ltd 2101 Beneficial owner
Fan Daidi 2201 Interest of corporation controlled by you
Yan Jianya 2202 Interest of your spouse
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Yan Jianya 2101 Beneficial owner
Fan Daidi
Trident Trust Company (b.v.i.) Limited 2301 Trustee

Giant Biogene Holding Co (HKSE:02367) Headlines

No Headlines